BioSpace News Archive

AMRA Medical announced today that the AMRA ® MAsS Scan has received a 510(k) clearance from the FDA.

Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the quarter ended September 30, 2021.

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 14,500 shares of the company’s common stock to two new employees as inducement awards under the company’s 2019 Inducement Plan.

L3Harris Technologies (NYSE:LHX) has completed the sale of its Narda-MITEQ business to an investment affiliate of J.F. Lehman & Company.

Foldax® , Inc. today announced that the Drugs Controller General of India (DCGI), India’s regulatory body for medical devices, has approved initiation of a clinical trial of the TRIA™ biopolymer surgical aortic heart valve.

Science 37, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System, today announced it has added capability to meet regulatory requirements and deploy its full-stack, end-to-end technology platform into China and Russia,

Vincerx Pharma, Inc. (Nasdaq: VINC), today announced that the European Commission has granted Orphan Drug Designation to VIP152, the Company’s PTEFb/CDK9 inhibitor, for the treatment of diffuse large B-cell lymphoma (DLBCL).

Providence Therapeutics announced today that their COVID-19 vaccine program, PTX-COVID19-B, has received $2.118 Million USD in funding from the Bill & Melinda Gates Foundation.

Kintara Therapeutics, Inc today announced that its Chief Executive Officer, Robert E. Hoffman, will present a corporate overview at the MedInvest Oncology Investor Conference, which is being held virtually on December 7 – 10, 2021.

Anthos Therapeutics, announced today that it has completed enrollment in the AZALEA-TIMI 71 clinical trial, a Phase 2 randomized, multicenter, active-controlled study evaluating the safety and tolerability of abelacimab in comparison with open-label rivaroxaban in patients with atrial fibrillation at moderate-to-high risk of stroke.